However, based on preclinical data, monotherapy with PI3K inhibitors seems to be insufficient in tumors harboring KRAS mutations as the RAF-MEK-ERK pathway hijacks tumor growth through compensatory mechanisms. Here, MAP2K7 is linked to neoplasm.